Zoetis Inc. $ZTS Stock Holdings Cut by Choreo LLC

Choreo LLC reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 30.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,049 shares of the company’s stock after selling 6,637 shares during the quarter. Choreo LLC’s holdings in Zoetis were worth $1,902,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC boosted its stake in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares in the last quarter. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis during the 4th quarter worth $25,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis during the 4th quarter worth $30,000. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Zoetis during the 3rd quarter worth $31,000. Finally, Holos Integrated Wealth LLC bought a new stake in shares of Zoetis during the 4th quarter worth $32,000. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

NYSE ZTS opened at $121.11 on Wednesday. Zoetis Inc. has a fifty-two week low of $113.29 and a fifty-two week high of $172.23. The stock’s 50-day moving average is $122.10 and its two-hundred day moving average is $126.74. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market cap of $50.94 billion, a P/E ratio of 20.12, a price-to-earnings-growth ratio of 1.83 and a beta of 0.98.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period last year, the company earned $1.40 earnings per share. The business’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s payout ratio is presently 35.22%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Bank of America raised their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Piper Sandler restated a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Finally, UBS Group set a $136.00 price target on Zoetis in a research note on Thursday, January 29th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.